secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2025-04-11T23:59:59+00:00
Accession:  0001104659-25-034283
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 3.03, 5.03, 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros receives Nasdaq equity deficiency delisting notice; shareholders approve massive share increase and reverse split
--------------------------------------------------------------------------------

- Nasdaq notified Petros on Apr 8 it fails $2.5M minimum stockholders' equity requirement, adding to existing bid price deficiency.
- All delisting actions stayed pending hearing before Nasdaq Hearings Panel; company intends to address concerns.
- At special meeting Apr 10, stockholders approved increasing authorized common shares from 250M to 7B.
- Also approved reverse stock split at ratio of 1-for-250 to 1-for-500, at Board's discretion.
- Approved increase in incentive plan shares by 1B to 1,002,760,000, and issuance of shares underlying Series Warrants from Feb 2025 offering (approx 1.06B shares).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465925034283/0001104659-25-034283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465925034283/tm2512195d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-034283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer